About Contact Us Careers
Sign In

Asthma and COPD Drugs Market Size & Share, by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous); Distribution Channel (General Pharmacies, Hospital Pharmacies, Online Retailers); End-user (Asthma Patients, COPD Patients) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4116
  • Published Date: May 23, 2023
  • Report Format: PDF, PPT

Companies dominating the Asthma and COPD Drugs Landscape

top-features-companies
    • GlaxoSmithKline plc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Sanofi
    • CHIESI Farmaceutici S.p.A.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Abbott
Browse Key Market Insights with Data Illustration:

In the News

  • Dignity Health, and Propeller Health announced that they have integrated Propeller’s platform into Dignity Health’s electronic health record (EHR) system, which is fully implemented in seven communities served by Dignity Health physicians and clinics in Arizona and California.
  • True Corporation along with partners, Easy Asthma & COPD Clinics (EACC), a network of respiratory disease treatment clinics, and GlaxoSmithKline Thailand (GSK), a researcher and developer of innovative drugs and vaccines, launched “Telehealth Together” project to take care of patients suffering from respiratory diseases using True's health intelligent healthcare platform for telehealth services.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4116
  • Published Date: May 23, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

High prevalence and incidence of asthma and COPD, decreasing environmental air quality, and the presence of harmful gases and particles are the major factors driving the market growth.

The market size of asthma and COPD drugs is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2023-2035.

The side effects associated with respiratory drugs are estimated to be the growth hindering factor for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are GlaxoSmithKline plc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, CHIESI Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Abbott, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by route of administration, distribution channel, end user, and by region.

The COPD patients segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying